This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
EIP Pharma, LLC
Drug Names(s): VX-745
Description: VX-745 specifically inhibits the intra-cellular enzyme p38 mitogen activated protein kinase alpha (MAPK alpha).
In a collaboration with Kissei that began in 1997, Vertex is pioneering the discovery and development of novel p38 MAP kinase inhibitors. Under the agreement, Vertex holds the development and commercial rights in the United States and Europe for its p38 MAP kinase inhibitors. Kissei holds development and commercial rights in Japan and certain Asian countries for VX-745.
In 2012, VX-745 was licensed by EIP Pharma for development in central nervous system (CNS) disorders from Vertex Pharmaceuticals.
Partners: Vertex Pharmaceuticals Incorporated
Pink Sheet Vertex stops VX-745 trials
Pink Sheet FDA ‘Breakthrough Therapy’ Designations
Additional information available to subscribers only: